



Improving People's Lives Through Innovations in Personalized Health Care

# Promoting Cognitive Health Among Youth with Psychosis

Nicholas Breitborde, PhD  
Department of Psychiatry and Behavioral Health




**THE OHIO STATE UNIVERSITY**


WEXNER MEDICAL CENTER

# Global Burden of Disease Study 2013


Illness/Injury	Disability Weight
<b><u>Schizophrenia, Acute State</u></b>	<b><u>0.778</u></b>
Spinal cord lesion, At neck: Untreated	0.732
Multiple sclerosis, Severe	0.719
Heroin and other opioid dependence, Moderate to severe	0.697
Major depressive disorder, Severe Episode	0.658
Traumatic brain injury, Long-term consequences, severe, with or without treatment	0.637
Spinal cord lesion, Below neck, untreated	0.623
Spinal cord lesion. At neck, Treated	0.589
<b><u>Schizophrenia, Residual State</u></b>	<b><u>0.588</u></b>
Stroke, Long-term consequences, severe, plus cognitive problems	0.588



# Disease-Related Burden in First-Episode Psychosis






Cognitive measure	First-episode schizophrenia (FES)	Youth-onset schizophrenia (YOS)	Late-onset schizophrenia (LOS)	$Q_{\text{between}}$	FES v. YOS v. LOS <sup>a</sup>
Full-scale IQ	0.89 (0.04)	1.77 (0.07)	1.61 (0.15)	121.64***	FES < YOS, FES < LOS, YOS = LOS
Verbal IQ	1.31 (0.08)	1.19 (0.13)	1.34 (0.16)	0.75	–
Performance IQ	1.73 (0.09)	1.25 (0.15)	2.07 (0.23)	11.75**	FES = YOS = LOS
Global measure of cognition	0.67 (0.10)	–	1.67 (0.11)	45.74***	FES < LOS
Digit symbol coding	1.46 (0.05)	1.46 (0.09)	0.29 (0.22)	27.18***	FES = YOS, LOS < FES, LOS < YOS
Tower of London and similar tests	0.78 (0.05)	0.57 (0.08)	0.97 (0.15)	8.18*	FES = YOS = LOS
Visual memory	0.85 (0.03)	0.95 (0.10)	1.12 (0.09)	9.46**	FES = YOS = LOS
Verbal general memory	1.03 (0.03)	0.98 (0.07)	1.11 (0.13)	0.86	–
Vocabulary	1.02 (0.05)	1.18 (0.11)	0.42 (0.19)	11.76**	FES = YOS, FES = LOS, LOS < YOS
Arithmetic	0.99 (0.07)	1.37 (0.12)	0.24 (0.26)	17.74***	FES = YOS, FES = LOS, LOS < YOS
Fluency	0.87 (0.03)	0.96 (0.10)	1.47 (0.14)	17.50***	FES = YOS, FES < LOS, YOS = LOS
Visual attention	0.72 (0.03)	0.66 (0.08)	1.51 (0.15)	26.72***	FES = YOS, FES < LOS, YOS < LOS
Stroop test	0.86 (0.04)	1.14 (0.13)	1.76 (0.27)	14.20**	FES = YOS = LOS
Continuous Performance Test	0.83 (0.04)	0.73 (0.08)	–	1.17	–
Visuospatial construction	0.83 (0.03)	0.98 (0.08)	1.41 (0.18)	12.97**	FES = YOS = LOS
Trail making test B	0.77 (0.05)	1.12 (0.10)	–	9.82**	FES < YOS
Verbal special memory	0.94 (0.03)	1.18 (0.06)	1.20 (0.12)	15.04***	FES < YOS, FES = LOS, YOS = LOS
Trail making test A	0.66 (0.04)	0.70 (0.10)	–	8.82*	FES < YOS
Wisconsin card sorting and similar tests	0.76 (0.03)	2.00 (0.08)	1.13 (0.12)	231.41***	FES < YOS, FES = LOS, LOS < YOS
Psychomotor speed of processing	0.65 (0.02)	0.92 (0.06)	1.01 (0.21)	19.68***	FES < YOS, FES = LOS, YOS = LOS
Auditory attention	0.61 (0.08)	0.53 (0.12)	1.95 (0.27)	23.47***	FES = YOS, FES < LOS, YOS < LOS
Digit span	0.64 (0.04)	0.85 (0.10)	0.87 (0.12)	6.69*	FES = YOS = LOS







### Community Functioning




### Social Behavior in the Milieu



### Social Problem Solving



### Social Skills





## Special Communication

# Schizophrenia Is a Cognitive Illness Time for a Change in Focus

René S. Kahn, MD, PhD; Richard S. E. Keefe, PhD


Schizophrenia is currently classified as a psychotic disorder. This article posits that this emphasis on psychosis is a conceptual fallacy that has greatly contributed to the lack of progress in our understanding of this illness and hence has hampered the development of adequate treatments. Not only have cognitive and intellectual underperformance consistently been shown to be risk factors for schizophrenia, several studies have found that a decline in cognitive functioning precedes the onset of psychosis by almost a decade. Although the question of whether cognitive function continues to decline after psychosis onset is still debated, it is clear that cognitive function in schizophrenia is related to outcome and little influenced by antipsychotic treatment. Thus, our focus on defining (and preventing) the disorder on the basis of psychotic symptoms may be too narrow. Not only should cognition be recognized as the core component of the disorder, our diagnostic efforts should emphasize the changes in cognitive function that occur earlier in development. Putting the focus back on cognition may facilitate finding treatments for the illness before psychosis ever emerges.

*JAMA Psychiatry*. 2013;70(10):1107-1112. doi:10.1001/jamapsychiatry.2013.155  
Published online August 7, 2013.

← Editorial page 1009


**Author Affiliations:** Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, UMC Utrecht, Utrecht, the Netherlands (Kahn); Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina (Keefe).

**Corresponding Author:** René S. Kahn, MD, PhD, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, UMC Utrecht, Utrecht, Heidelberglaan 100, 3508 GA Utrecht, PO Box 85500, the Netherlands (r.kahn@umcutrecht.nl).




# Glutamate Modulators and NMDA Receptors





### Molecular Psychiatry





**Study name**

**Statistics for each study**

Study name	Hedges's g	Standard error	Variance	Lower limit	Upper limit	Z-Value	Total	p-Value
Behere et al. 2011	0.469	0.321	0.103	-0.160	1.097	1.461	39	0.144
Campos et al. 2015	-0.016	0.363	0.132	-0.727	0.695	-0.044	29	0.965
Ho et al. 2016	0.333	0.200	0.040	-0.059	0.725	1.665	100	0.096
Kimhy et al. 2015	0.905	0.400	0.160	0.121	1.689	2.262	26	0.024
Lin et al. 2015	0.402	0.253	0.064	-0.093	0.897	1.590	64	0.112
Nuechterlein et al. 2016	0.792	0.497	0.247	-0.181	1.766	1.595	16	0.111
Oertel-Knochel et al. 2014	0.308	0.449	0.202	-0.572	1.187	0.685	19	0.493
Pajonk et al. 2010	0.615	0.485	0.235	-0.336	1.566	1.267	16	0.205
Svatkova et al. 2015	0.199	0.341	0.116	-0.468	0.867	0.585	33	0.558
Malchow et al. 2015	-0.151	0.311	0.097	-0.760	0.458	-0.487	41	0.626
	0.334	0.102	0.010	0.134	0.533	3.279	383	0.001

**Hedges's g and 95% CI**







ELSEVIER

Contents lists available at ScienceDirect

## Sleep Medicine Reviews

journal homepage: [www.elsevier.com/locate/smr](http://www.elsevier.com/locate/smr)



### CLINICAL REVIEW

## A systematic review of the nature and correlates of sleep disturbance in early psychosis



Gabriel Davies <sup>a, b, \*</sup>, Gillian Haddock <sup>a, b</sup>, Alison R. Yung <sup>c, d</sup>, Lee D. Mulligan <sup>d</sup>,  
Simon D. Kyle <sup>e</sup>

<sup>a</sup> School of Psychological Sciences, University of Manchester, UK

<sup>b</sup> Manchester Mental Health and Social Care NHS Trust, Manchester, UK

<sup>c</sup> Institute of Brain, Behaviour and Mental Health, University of Manchester, UK

<sup>d</sup> Greater Manchester West NHS Trust, Manchester, UK

<sup>e</sup> Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK





Contents lists available at [ScienceDirect](#)

## Schizophrenia Research

journal homepage: [www.elsevier.com/locate/schres](http://www.elsevier.com/locate/schres)



### Sleep and schizophrenia: From epiphenomenon to treatable causal target

Felicity Waite<sup>a,b,c,\*</sup>, Bryony Sheaves<sup>a,b,c</sup>, Louise Isham<sup>a,b</sup>, Sarah Reeve<sup>d</sup>, Daniel Freeman<sup>a,b,c</sup>

<sup>a</sup> Department of Psychiatry, University of Oxford, UK


<sup>b</sup> Oxford Health NHS Foundation Trust, UK


<sup>c</sup> Sleep and Circadian Neuroscience Institute, University of Oxford, UK

<sup>d</sup> University College London, UK



Hedges's g and 95% CI







# Cognitive Remediation Therapy


- Development of cognitive strategies
- Repeated practice of cognitive exercises
- Promotion of skills transfer to real world
- Delivered by a trained and active therapist

Outcome	Studies	Participants	Effect size (95% CI)
Global cognition	135	7813	0.29 (0.24-0.34)
Global functioning	95	6091	0.22 (0.16-0.29)
Attention	40	2483	0.17 (0.07-0.26)
Processing speed	80	4917	0.20 (0.14-0.26)
Working memory	93	5493	0.25 (0.19-0.31)
Verbal memory	81	4954	0.33 (0.25-0.41)
Visual memory	43	2970	0.25 (0.14-0.36)
Executive functions	86	5196	0.28 (0.20-0.36)
Social cognition	55	3389	0.24 (0.16-0.32)
Global symptoms	76	4735	0.14 (0.08-0.20)
Positive symptoms	79	4700	0.12 (0.06-0.18)
Negative symptoms	82	4892	0.14 (0.06-0.22)







## General Cognition



## Functional outcome



# Cognitive Remediation in Early Psychosis





# Targeting Metacognition

- Cognitive abilities can be enhanced through improving metacognitive awareness/abilities (Schraw et al., 2006)
- Metacognitive abilities may moderate association between cognitive functioning and real-world functioning (Koren et al., 2006)

## METACOGNITIVE INTERVENTIONS

AIM	<ul style="list-style-type: none"> <li>targeting metacognitive content by raising awareness and understanding of own thoughts and feelings and those of others</li> <li>enhancing metacognitive capacities by gaining more flexibility in the attention, monitoring, control, and regulation of cognitive processes</li> <li>alleviating disorder-specific and individual symptoms</li> </ul>
APPROACH	<ul style="list-style-type: none"> <li>individual problem formulation based on a metacognitive model of illness</li> <li>goal-oriented treatment</li> </ul>

	METACOGNITIVE THERAPY	METACOGNITIVE TRAINING	METACOGNITIVELY-ORIENTED INTEGRATIVE PSYCHOTHERAPIES
DEFINITION OF METACOGNITION	<ul style="list-style-type: none"> <li>beliefs about cognition</li> <li>strategies used to control attention and thinking</li> </ul>	<ul style="list-style-type: none"> <li>capacity to think about their thinking</li> <li>patients' awareness of their cognitive biases</li> </ul>	<ul style="list-style-type: none"> <li>ability to understand and make sense of own mental states and the mental states of others</li> </ul>
MODEL OF ILLNESS	<ul style="list-style-type: none"> <li>inflexible metacognitions (= positive and negative beliefs about cognition)</li> <li>result in disorder-specific <i>Cognitive Attentional Syndrome</i> (CAS)</li> </ul>	<ul style="list-style-type: none"> <li>disorder-specific cognitive biases</li> </ul>	<ul style="list-style-type: none"> <li>inability to construct and develop a coherent personal narrative</li> </ul>
KEY INTERVENTIONS	<ul style="list-style-type: none"> <li>challenging inflexible metacognitive beliefs in order to modify CAS</li> </ul>	<ul style="list-style-type: none"> <li>educating patients about cognitive processes and their negative consequences</li> <li>promote alternative thinking strategies</li> </ul>	<ul style="list-style-type: none"> <li>encouraging reflection</li> <li>enriching narratives</li> <li>constructing integrated sense of self and others</li> </ul>

# Metacognition—What is it?

- Metacognitive knowledge
  - Stored knowledge about cognitive processes of self and others
- Metacognitive experiences
  - Reflection/awareness about cognitive processes of self and others
- Goals/Tasks
  - Recognition of utility/desire to evaluate metacognitive experience
- Actions/Strategies
  - Activity employed to evaluate metacognitive experience


# MCR sessions

- Pairing of computerized cognitive remediation with metacognitive skills development exercises
  - Identification of strategies to enhance knowledge of cognition
  - Identification of strategies to enhance regulation of cognition
  - Exploration of intervening factors that may interfere with or enhance task knowledge/regulation of cognition
  - Real-world application of strategies

# Knowledge of Cognition

- GOAL = Improve knowledge of problem-solving skills for cognitive tasks:
  - Declarative Knowledge
    - “What Strategies Can I Use to Complete This Task?”
  - Procedural Knowledge
    - “How Do I Use Each Specific Strategy to Complete the Task?”
  - Conditional Knowledge
    - “Why Would This Strategy Work Best In A Specific Situation?”
- Exploring Real-World Applications

# Regulation of Cognition



# Intervening Factors

- Provide training in evidence-based strategies to address factors that may interfere with application of problem-solving strategies
  - Arousal Regulation
  - Mood Regulation
  - Self-Efficacy and Motivation

# Real-World Applications

- Bridging MCR Strategies to Real-World Situations
- Low Road vs High Road Transfer (Salomon & Perkins, 1989)







# Is MCR Metacognitive?


- Metacognitive knowledge
  - Enhance knowledge of problem-solving strategies and intervening factors that influence their success
- Metacognitive experiences
  - Increase ability to monitor implementation of problem-solving strategies
- Goals/Tasks
  - Enhance motivation to evaluate implementation of problem-solving strategies
- Actions/Strategies
  - Develop/master strategies to evaluate whether problem-solving strategies are achieving their goal

# MCR Outcomes

# MCR Improves Metacognition




# MCR Mechanisms of Change




*(indirect effect = 1.89; 95% CI = 0.07–5.20)*

# Social Functioning: CCR




\* $p < 0.05$

# Social Functioning: MCR




\*p < 0.05

# Intrinsic Motivation



Breitborde et al, 2018

# Therapeutic Alliance





# Conclusions

- Cognitive deficits are a core feature of psychotic disorders
- Multiple interventions of varying intensity show promise in addressing these cognitive deficits
- Not all cognitive remediation interventions may be effective for youth with psychosis